The potential vaccine that the pharmaceutical companies Pfizer and BioNTech are developing together is 90 percent effective against the corona virus. This is evident from interim results.
The two companies announced interim results for their coronavirus vaccine candidate on Monday. Research in 43,538 patients has shown that the vaccine works almost perfectly against the virus. Whoever gets it would be protected from Covid-19 28 days later.
However, it should be noted that these are preliminary results. After more research, that could still change, but experts agree that there is “nothing much better” at this stage.
Pfizer CEO Albert Bourla also speaks of a “historic day for science”. “We are approaching a critical milestone in the development of our vaccine at a time when the world needs it most due to rising infections and overcrowded hospitals,” said a press release. “We will continue to collect data for a final analysis when 164 more corona patients have been examined.”
The Pfizer vaccine is one of the candidates for a European vaccine. The European Commission has already ordered 200 million doses, with an option for 100 million more if it does its job properly. Pfizer plans to apply for emergency approval in the US in late November. In the third week of this month there would be enough data to start the process.
The vaccine is partly developed in Belgium. At the moment, a few hundred thousand bottles are already rolling off the production line at the Pfizer branch in Puurs-Sint-Amands in Antwerp.
The stock markets are already reacting euphorically. The pre-exchange trade in the US goes up to more than 5 percent, the European stock exchanges up to 7 percent.
And outgoing US President Donald Trump cannot hide his happiness either. On Monday he tweeted – somewhat prematurely – that a vaccine is on the way.